BridgeMD
New treatment option for Cervical Cancers
Official title The Effects of Immunonutrition Therapy on Locally Advanced Cervical Cancer Patients
ClinicalTrials.gov ID: NCT06349148
What this study is testing
- What it's testing
- The goal of this open-label randomized control trial is to study the effect of immunonutrition in locally advanced cervical cancer (LACC) with standard concurrent chemoradiotherapy. LACC patients undergoing radical synchronous chemoradiotherapy will be randomized into the experimental group receiving enteral immunonutrition therapy and the control group receiving standard enteral nutrition support.The main purpose it aims to answer are:1）Can immunonutrition therapy improve patients' dose-limiting toxicity(DLT) and DLT-free survival?
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Age ≥ 18 years;
- Pathological histological diagnosis confirmed as cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
- Confirmed as Locally Advanced Cervical Cancer (LACC) based on gynecological examination and imaging assessment;
- Undergoing CCRT/RT treatment;
- Patients are conscious, able to communicate without barriers, and able to answer questions.
You likely can't join if
- Patients who received neoadjuvant chemotherapy or immunotherapy before treatment;
- Patients with concomitant other malignant tumors or a history of malignant tumors;
- Patients with special pathological types of tumors such as cervical small cell carcinoma or neuroendocrine tumors;
- Patients staged as Ⅳb according to the International Federation of Gynecology and Obstetrics(FIGO) 2018 staging system;
- Patients with other severe chronic debilitating diseases, such as severe heart failure (New York Heart Association Class II-IV), severe liver damage...
- Eastern Cooperative Oncology Group(ECOG) performance status ≥ 2;
See the full eligibility criteria
- Age ≥ 18 years;
- Pathological histological diagnosis confirmed as cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
- Confirmed as Locally Advanced Cervical Cancer (LACC) based on gynecological examination and imaging assessment;
- Undergoing CCRT/RT treatment;
- Patients are conscious, able to communicate without barriers, and able to answer questions.
- diagnosed with malnutrition according to the GLIM criteria;
- Patients who received neoadjuvant chemotherapy or immunotherapy before treatment;
- Patients with concomitant other malignant tumors or a history of malignant tumors;
- Patients with special pathological types of tumors such as cervical small cell carcinoma or neuroendocrine tumors;
- Patients staged as Ⅳb according to the International Federation of Gynecology and Obstetrics(FIGO) 2018 staging system;
- Patients with other severe chronic debilitating diseases, such as severe heart failure (New York Heart Association Class II-IV), severe liver damage (alanine aminotransferase ≥ 3 times the upper limit of normal), severe...
- Eastern Cooperative Oncology Group(ECOG) performance status ≥ 2;
- Presence of other contraindications to CCRT/RT.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.